Santhera Pharmaceuticals Holding AG (0QN1)

London
Currency in CHF
Disclaimer
190.20
0.00(0.00%)
Closed
Trading near 52-week High
Day's Range
190.20190.20
52 wk Range
0.53190.20
Prev. Close
0.64
Open
190.2
Day's Range
190.2-190.2
52 wk Range
0.53-1.39
Volume
0
Average Volume (3m)
2,568
1-Year Change
14,419.08%
Shares Outstanding
11,661,725
Analysts
Technical
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
24.00
Upside +175.86%

Santhera Pharmaceuticals Holding AG Company Profile

Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and commercializes medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the European Union and internationally. The company’s lead pipeline candidate includes Vamorolone, which is being developed for the treatments of Duchenne muscular dystrophy (DMD). Its clinical stage pipeline also comprises Lonodelestat to treat cystic fibrosis and other neutrophilic pulmonary diseases, as well as omigapil that treats congenital muscular dystrophies. The company also out-licenses outside North America and France rights to its approved product, Raxone (idebenone), for the treatment of Leber's hereditary optic neuropathy. Santhera Pharmaceuticals Holding AG was founded in 2004 and is headquartered in Pratteln, Switzerland.

Employees
46

Income Statement